Sign In
Buy KZIA
$10.95
-0.84 (-7.12%)
At Close: Jun 03, 2026
Kazia Therapeutics Announces Collaboration and In-Licensing Agreement for First-in-Class PD-L1 Protein Degrader Program
08:30am, Tuesday, 07'th Oct 2025
SYDNEY , Oct. 7, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced an exclusive collaboration and in-licensing agreement (th
SYDNEY , Oct. 2, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today reported a substantial reduction in tumor burden from a single-pati
Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG
09:21am, Wednesday, 01'st Oct 2025
SYDNEY , Oct. 1, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage biotechnology company developing innovative therapies for brain cancers, today announced its participa
SYDNEY , Sept. 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced new findings from a collaborative research program led
Kazia Therapeutics Announces $2 Million Private Placement at Premium to Market
08:00am, Friday, 01'st Aug 2025
SYDNEY , Aug. 1, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement
SYDNEY , July 9, 2025 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA) is pleased to announce preliminary results from the first patient in its Phase 1b trial evaluating a combination regimen of Paxa
SYDNEY , June 11, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a clinical-stage biotechnology company pioneering next-generation oncology therapeutics, today announced the publicati
Kazia Therapeutics Announces First Patient Dosed in Phase 1b Trial of Paxalisib in Advanced Breast Cancer
08:00am, Thursday, 05'th Jun 2025
Trial is expected to provide key insights on how paxalisib therapy can be combined with established immunotherapies and standard of care chemotherapy to improve patient outcomes in advanced breast can
Kazia Therapeutics Highlights Recent Progress and Provides Business Update
08:00am, Thursday, 15'th May 2025
Awarded research grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to fund research between The Hebrew University of Jerusalem (Hebrew University) and Kazia to explore the thera
Kazia Therapeutics Announces Sale of Intellectual Property and Trademarks Rights for Cantrixil
07:30am, Monday, 31'st Mar 2025
Kazia to receive USD $1 million from Vivesto for the intellectual property and trademark assets rights to the oncology drug candidate, Cantrixil SYDNEY , March 31, 2025 /PRNewswire/ -- Kazia Therapeut
SYDNEY , Jan. 30, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) an oncology-focused drug development company, is pleased to announce the regulatory approval and launch of a clinical
Kazia Therapeutics Announces Closing of $2.0 Million Registered Direct Offering
04:00pm, Tuesday, 14'th Jan 2025
SYDNEY , Jan. 14, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has closed its previo
Kazia Therapeutics Announces $2.0 Million Registered Direct Offering
09:58am, Friday, 10'th Jan 2025
SYDNEY , Jan. 10, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA) ("Kazia" or the "Company"), an oncology-focused drug development company, today announced that it has entered into a de
Why Is Brain Cancer-Focused Kazia Therapeutics Stock Trading Lower On Tuesday?
12:34pm, Tuesday, 31'st Dec 2024
Kazia Therapeutics Limited KZIA stock is trading lower on Tuesday after the company provided a regulatory update on paxalisib for glioblastoma (GBM) following its Type C clinical meeting with the FDA.
Kazia Therapeutics Provides Update on Paxalisib Regulatory Pathway Following Type C Meeting with FDA
08:00am, Tuesday, 31'st Dec 2024
SYDNEY , Dec. 31, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today provided a regulatory update on paxalisib for the treatment of gli
